Peroxiredoxin 4（PRDX4）是最近发现的一种抗氧化蛋白，是PRDX家族中唯一一个分泌型蛋白。在以前的实验中，我们研究了PRDX4在糖尿病、动脉硬化中的作用机制，特别是最近发现脂肪肝时, PRDX4可明显降低肝组织细胞及外周血中的活性氧簇分子(ROS)水平，减少其对肝细胞的损害，从而抑制疾病的进展。与之类似，肝癌时ROS水平也会显著升高，它被认为是肿瘤生长的必要物质基础，在癌症进展中起着重要的作用。由此我们推测PRDX4能够降低肝癌组织细胞内外的ROS水平，进而从多方面来抑制肝癌的进展。此外，抗氧化治疗癌症是一个争论激烈的研究领域，许多问题悬而未决。本研究拟通过对PRDX4转染肝癌细胞和转基因小鼠的研究，来进一步揭示PRDX4在肝癌中的作用机制，为抗氧化酶在癌症治疗中的应用提供理论依据，给癌症治疗提供一条新思路。

Peroxiredoxin 4 (PRDX4), recently identified an anti-oxidative protein, is only one secreted protein of PRDX antioxidant protein family. In our previous studies, we investigated the role of PRDX4 in diabetes and atherosclerosis, especially found that when fatty liver, it can reduce the level of reactive oxygen species (ROS) in tissues and cells and blood, attenuate ROS-injury to liver cells and prevent the progress of the diseases. Similarly, in liver cancer, the ROS lever will increase dramatically, which is essential for tumor growth and plays important roles in the development of cancer. We speculate that PRDX4 can reduce the ROS level in inside and outside of liver cancer cells and control the development of liver cancer in many ways. Moreover, the role of anti-oxidative in cancer therapy is controversial, and lots of problems remain unknown. This study will further illustrate the role of oxidative stress in liver cancer, give theory evidences for application of antioxidase in cancer therapy and provide a new thinking for cancer therapy，utilizing liver cell line and transgenic mice by transfection and induced liver cancer.